Evidence mapPaperPMID 42280468Full record

Trial reportNutrients2026

1,5-Anhydro-D-Mannitol Is a Potentially Low-Energy Carbohydrate: A Dual-Model Approach in Rats and a Randomized, Three-Way Crossover Trial in Humans.

Kenichi Tanabe, Ikuma Tanaka, Hiromi Hayashi, Kazuhiro Yoshinaga, Sadako Nakamura

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kenichi TanabeDepartment of Nutritional Science, Faculty of Nutritional Sciences, Nakamura Gakuen University, 5-7-1 Befu, Jonan-Ku, Fukuoka 814-0198, Japan.ORCID 0000-0002-4386-535X
Ikuma TanakaGraduate School of Nutritional Science, Nakamura Gakuen University, 5-7-1 Befu, Jonan-Ku, Fukuoka 814-0198, Japan.ORCID 0009-0003-8476-6467
Hiromi HayashiSUNUS Co., Ltd., 20 Nanei 3-Chome, Kagoshima City 891-0196, Japan.
Kazuhiro YoshinagaSUNUS Co., Ltd., 20 Nanei 3-Chome, Kagoshima City 891-0196, Japan.
Sadako NakamuraGraduate School of Human Life Sciences, Jumonji University, 2-1-28 Sugasawa, Niiza 352-8510, Japan.ORCID 0000-0003-3649-9694

Funding

Ministry of Economy, Trade and Industry JPJ005698
6 · The paper itself

Abstract

BACKGROUND/

objectivesWe hypothesized that orally ingested 1,5-anhydro-D-mannitol (AM) would be absorbed from the gut but poorly metabolized, and it may have low fermentability by gut microbiota based on the breath hydrogen test.

methodsWe used a dual-model approach in this study. In animal experiments, AM was administered orally to male Wistar rats. In a randomized, three-way crossover trial (UMIN000054040), 15 healthy young adults consumed a single 5 g dose of AM, mannose, or fructooligosaccharide (FOS). Primary outcome was breath hydrogen concentrations; secondary outcomes included plasma AM, blood glucose concentration, and urinary AM excretion.

resultsAfter ingestion of 5 g AM in humans, the 14 h area under the curve for breath hydrogen excretion was markedly lower after AM than that after FOS ingestion (

conclusionsThese findings indicate that AM is potentially a low-energy carbohydrate.

Indexed as

Dietary CarbohydratesMannitolAdministration, OralAdultAnimalsBlood GlucoseBreath TestsCross-Over StudiesHumansHydrogenMaleMannoseOligosaccharidesRatsRats, WistarYoung AdultBlood GlucoseDietary CarbohydratesfructooligosaccharideHydrogenMannitolMannoseOligosaccharides1,5-anhydro-D-mannitolbioavailabilitybreath hydrogen gascrossover studygut fermentationurinary excretion

Identifiers

PMID42280468
PMCPMC13259140

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.